Detecting exon deletions and duplications of the DMD gene using Multiplex Ligation-dependent Probe Amplification (MLPA).

  title={Detecting exon deletions and duplications of the DMD gene using Multiplex Ligation-dependent Probe Amplification (MLPA).},
  author={Kent K S Lai and Ivan Fai-Man Lo and Tony Ming-For Tong and Lydia Y.L. Cheng and Stephen Tak-sum Lam},
  journal={Clinical biochemistry},
  volume={39 4},

Figures and Tables from this paper

Improved Detection of Deletions and Duplications in the DMD Gene Using the Multiplex Ligation-Dependent Probe Amplification (MLPA) Method

This study confirmed MLPA to be the method of choice for detecting DMD gene rearrangements in DMD/BMD patients, showed that ambiguous MLPA amplification products should be verified by other methods, and indicated that the MLPA method could be used in screening even for small mutations located in the probe-binding regions.

Use of multiplex ligation-dependent probe amplification (MLPA) for Duchenne muscular dystrophy (DMD) gene mutation analysis.

The systematic approach/algorithm used in this study offers the best possible economical mutation analysis in the Indian scenario.

[Evaluation of multiplex PCR assay using dual priming oligonucleotide system for detection mutation in the Duchenne muscular dystrophy gene].

DPO PCR shows a high agreement of results with the conventional PCR and is considered an adequate method to be used as a primary genetic test for the diagnosis of DMD.

Small mutations detected by multiplex ligation-dependent probe amplification of the dystrophin gene.

Results show that MLPA can serve as a tool for screening small mutations, as well as for detecting exon deletions or duplications, in Duchenne and Becker muscular dystrophies patients.

Dystrophin gene mutation analysis in Iranian males and females using multiplex polymerase chain reaction and multiplex ligation-dependent probe amplification methods.

The multiplex ligation-dependent probe amplification (MLPA) method proved to be reliable for studying affected males as well as female carriers for dystrophin gene deletions and duplications.

Targeted sequencing of the DMD locus: A comprehensive diagnostic tool for all mutations

The findings showed the importance of NGS in the routine diagnostic practice in the identification of DMD mutations over sequential testing and may be used as a single-point diagnostic strategy irrespective of the mutation type, thereby reducing the turnaround time and cost for multiple diagnostic tests such as MLPA and Sanger sequencing.

Characteristics of dystrophin gene mutations among Chinese patients as revealed by multiplex ligation-dependent probe amplification.

For the comprehensive coverage of all exons of the dystrophin gene, MLPA should be the method of choice for initial screening of DMD/BMD patients, when combined with STR-based analysis, it can achieve diagnosis in as much as 70-80% of all referred cases.



Deletion and duplication screening in the DMD gene using MLPA

The MLPA assay provides a simple and cheap method for deletion and duplication screening in DMD/BMD patients and outperforms the Beggs and Chamberlain multiplex-PCR test, and should be considered as the method of choice for an initial DNA analysis of patients.

Identification of deletions and duplications of the DMD gene in affected males and carrier females by multiple ligation probe amplification (MLPA)

MLPA analysis proved to be an useful tool for the analysis of both affected males and females carriers of DMD rearrangements in cases in which the disease-causing mutation in the affected male was not known, providing useful information for the genetic counselling of the family.

Improved molecular diagnosis of dystrophin gene mutations using the multiplex ligation-dependent probe amplification method.

The newly developed quantitative assay multiplex ligation-dependent probe amplification (MLPA) method is used to determine the copy number of each of the 79 DMD exons in 182 males and 14 carrier females referred to the diagnostic facility on the clinical suspicion of DMD or BMD.

MLPA analysis for the detection of deletions, duplications and complex rearrangements in the dystrophin gene: potential and pitfalls

It is concluded that the novel multiplex ligation-dependent probe amplification (MLPA) method is a highly sensitive and rapid alternative to multiplex PCR and can be used on blood samples, chorionic villi and paraffin-embedded tissue.

Accurate diagnosis of carriers of deletions and duplications in Duchenne/Becker muscular dystrophy by fluorescent dosage analysis.

Together these two multiplex assays detect over 70% of all mutations in the dystrophin gene, greatly simplifying and partly automating molecular diagnosis in Duchenne and Becker muscular dystrophy.

Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction

Using oligonucleotide primer sequences that can be used to amplify eight exons plus the muscle promoter of the dystrophin gene in a single multiplex polymerase chain reaction (PCR) will allow deletion detection and prenatal diagnosis for most DMD/BMD patients in a fraction of the time required for Southern blot analysis.

Rapid identification of female carriers of DMD/BMD by quantitative real‐time PCR

The method proved to be simple, rapid, reliable, and cost‐effective for direct determination of deletions/duplications in potential DMD/BMD carriers and may easily be adapted for other genetic conditions involving deletions and duplications.

Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications.

The combination of cDNA hybridizations with long-range analysis of deletion and duplication patients yields a global picture of the exon spacing within the dystrophin gene.

Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method.

A novel method to detect single or multiple exon deletions and amplifications in the BRCA1 gene, called multiplex ligation-dependent probe amplification (MLPA), ensures a sensitive and comprehensive high-throughput screening test for genomic rearrangement.